Last Updated : March 21, 2025
Details
Generic Name:
risperidone
Project Status:
Received
Therapeutic Area:
Schizophrenia, adults
Manufacturer:
Bausch Health, Canada Inc.
Call for patient/clinician input open:
Brand Name:
Okedi
Project Line:
Reimbursement Review
Project Number:
SR0879-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of schizophrenia in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | February 06, 2025 |
|---|---|
| Call for patient/clinician input closed | March 31, 2025 |
| Submission received | March 21, 2025 |
| Submission accepted | - |
Last Updated : March 21, 2025